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Introduction: The majority of ovarian cancer recurrences are in the abdomen. However, some cases relapse as
isolated lymph node metastases, mostly in pelvic or para-aortic nodes. Peripheral isolated lymph node metastasis is
rare.
Case presentation: A 69-year-old Japanese woman had recurrent ovarian cancer presenting with isolated right
supraclavicular lymph node metastasis. After surgical resection and combination chemotherapy with carboplatin
and paclitaxel, her right supraclavicular lymph node completely regressed.
Conclusions: Peripheral isolated lymph nodes, including right supraclavicular lymph node, can recur without a
macroscopic abdominal lesion. Clinicians should carefully examine peripheral lymph nodes for recurrence.Introduction
The majority of ovarian cancer (OC) recurrences are
within the abdomen. However, some cases relapse as iso-
lated lymph node metastases, mostly in pelvic or para-
aortic nodes; peripheral isolated lymph node metastasis
is rare. Left supraclavicular lymph node (LSCLN), better
known as Virchow’s node, collects lymph through the
thoracic duct and from most areas of the body (mainly
the abdomen). A finding of an enlarged node has been
regarded as strongly indicative of the presence of cancer
in the abdomen. In contrast, right supraclavicular lymph
node (RSCLN) takes its supply mainly from the medias-
tinum, lungs, and esophagus [1]. We report a case of re-
current OC presenting with an isolated RSCLN
metastasis with no evidence of any other recurrent part
after 52 months from initial surgery.Case presentation
A 65-year-old post-menopausal Japanese woman (grav-
ida 2, para 2) with abdominal distension had an ovarian
tumor that was 15 cm in diameter. She had a medical
history of vaginal hysterectomy because of a uterine* Correspondence: tomohito@ommcp.jp
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distribution, and reproduction in any mediumprolapse after menopause at the age of 55 years. Her
levels of serum cancer-related antigen 125 (CA125) and
carbohydrate antigen 19-9 (CA19-9) were 170.0U/mL
(normal range is 0 to 35U/mL) and 15.1U/mL (normal
range is 0 to 37U/mL), respectively. She underwent a bi-
lateral salpingo-oophorectomy, an omentectomy, and a
pelvic lymphadenectomy. The surgery revealed that the
tumor originated from her bilateral ovaries. No evidence
of pelvic spread, peritoneal implantation, or ascites was
found. The results of a peritoneal washing cytological
examination were negative. On palpation, the para-aortic
lymph nodes were found not to be swollen. The final
diagnosis was stage Ib serous adenocarcinoma. The
serum concentration of CA125 decreased to below the
normal limit after surgical removal of the tumor. Subse-
quently, our patient underwent six cycles of paclitaxel
(180 mg/m2; three-hour intravenous infusion) given on
day one plus carboplatin of the area under the curve
(AUC) of 5 mg given on day one of a 21-day cycle (TC).
Follow-up abdominal and pelvic computed tomography
(CT) at the end of chemotherapy showed no evidence of
recurrent or residual lesions in the pelvis. After
52 months from the initial surgery, our patient found a
firm mass in her right supraclavicular area. There was
no evidence of other lymphadenopathy, ascites, or ab-
dominal masses. The results of a breast examinationCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Fluorine-18 fluorodeoxyglucose positron emission
tomography associated with computed tomography images
revealed an area of increased metabolic activity only in the
right supraclavicular lymph node (arrows).
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there were no skin lesions. The serum CA125 level
increased to 69.6U/mL. CT demonstrated RSCLN swol-
len to 15 mm in diameter. Other examinations, such as
mammography, chest and abdominal CT, gastroscopy,
colonoscopy, and gallium-67 scintigraphy, revealed no
abnormal findings. A core needle biopsy showed adeno-
carcinoma, similar to the findings from the primary OC:
our patient had a clinical diagnosis of isolated RSCLN
metastasis from OC. On palpation, the mass was immo-
bile and adhered well to a wide vessel surface. Surgical
resection might have placed our patient at risk of peri-
operative mortality. Our patient then underwent neoadju-
vant chemotherapy of dose-dense paclitaxel (80 mg/m2;
one-hour intravenous infusion) given on days one, eight,
and 15 plus carboplatin in the AUC of 5 mg given on day
one of a 21-day cycle (wTC). After three cycles of wTC,
the serum CA125 level decreased to the normal range and
the relapse lesion could not be palpated. The relapse le-
sion was also undetected on CT and was completely
regressed. Our patient was then given another three cycles
of wTC without surgical resection. However, 17 months
after the relapse was noticed, our patient found the
RSCLN growing again. Fluorine-18 fluorodeoxyglucose
positron emission tomography associated with computed
tomography (PET/CT) images revealed an area of
increased metabolic activity only in the RSCLN (Figure 1).
Our patient underwent surgical resection because the re-
lapse lesion was highly mobile and seemed to have no ad-
hesion. After the surgical resection, four cycles of wTC
were administered. Our patient was free of disease at a
20-month follow-up consultation after the resection of
RSCLN.
At the initial surgery, the diameters of the right and
left ovarian tumors were 120 × 78 × 60 mm and
80 × 68 × 60 mm, respectively. The tumors had smooth
lobulated external surfaces. The cut surfaces revealed
multiple papillary solid nodules within a thick-walled
unilocular cyst containing yellowish serous fluid. A
microscopic examination showed that the tumors were
composed of closely packed irregular papillae, most of
which had fibrous cores, lined with cells with stromal in-
vasion. The tumor cells had atypical nuclei with promin-
ent nucleoli and high nuclear-to-cytoplasmic ratios.
Psammoma bodies were occasionally seen (Figure 2a).
Immunohistochemically, the tumor cells were positive
for cytokeratin 7 (CK7) and CA125 and negative for
CK20 and CA19-9. The staining for Wilms’ tumor 1
protein (WT1) was positive in the nuclei of the cancer
cells.
In contrast, a specimen from RSCLN showed findings
similar to those in the ovaries. The tumor cells, com-
posed of cuboidal cells with oval to round nuclei, had
papillary infiltration. Psammoma bodies were frequentlyseen (Figure 2b). Immunohistochemically, the tumor
cells were positive for CK7, CA125, and WT1 and nega-
tive for CK20 and CA19-9.Discussion
The most common routes for the spread of epithelial
OC are lymphatic dissemination and transcoelomic
spread through the nearby internal organs [2]. Although
isolated lymph node recurrence (ILNR) of OC is rela-
tively rare, the literature includes several reports of large
numbers of ILNRs [3-9]. In these reports, ILNR oc-
curred in about 4% to 6% [3,4] of patients with OC,
representing approximately 10% [3] of the overall recur-
rences. In contrast, the clinical presentation of extra-
abdominal lymphadenopathy without abdominal mass
can occur before evidence of ovarian mass [10]. In 205
patients with ILNR of OC, although the most frequently
involved sites were para-aortic or pelvic or both, other
sites, such as left supraclavicular (eight cases), inguinal
(24 cases), axillary (one case), and mediastinal (five
cases), may also be involved. However, no patient had
ILNR in RSCLN. To the best of our knowledge, only one
case report about metastatic OC of RSCLN has been
Figure 2 Histological findings of the tumor. (a) The primary ovarian tumor was composed of closely packed irregular papillae, some of which
had fibrous cores, lined by cells with stromal invasion. The tumor cells had atypical nuclei with prominent nucleoli and high nuclear-to-
cytoplasmic ratios. Psammoma bodies were occasionally seen (upper left). (b) A specimen from right supraclavicular lymph node composed of
cuboidal cells with oval to round nuclei with papillary infiltration. Psammoma bodies were frequently seen. (a,b) Stain: hematoxylin and eosin;
magnification: ×400.
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RSCLN involvement where the primary OC manifested
after three years of clinical surveillance.
We hypothesize that the ILNR routes in OC include
either lymphatic dissemination or lymphatic dissemin-
ation after transcoelomic spread. LSCLN collects lymph
through the thoracic duct and from most areas of the
body. In contrast, RSCLN takes its supply mainly from
the mediastinum, lungs, and esophagus [1]; in a patient
with OC, the route of ILNR in LSCLN is lymphatic dis-
semination, and that in RSCLN is lymphatic dissemin-
ation from the transcoelomic spread site. In the present
case, although the diagnosis of ILNR was surgically con-
firmed, the suspected presence of a peritoneal lesion was
based on PET/CT findings. Bristow et al. [12] documen-
ted the presence of occult intraperitoneal disease in
21.4% of ILNR cases even when PET/CT scanning tech-
niques were used. Thus, we think that, in the present
case, the route was possibly lymphatic dissemination
from occult peritoneal disease.
Treatment for ILNR of OC is based on various factors,
such as the recurrence site, the general condition of the
patient, disease-free interval, growth rate, and response
to chemotherapy. Although these confounding factors
could be more adequately assessed through a multivari-
ate analysis of a larger number of patients, there are sev-
eral reports about therapy for ILNR of OC. Those
reports indicated that surgical removal of ILNR with or
without adjuvant therapy, such as chemotherapy, radi-
ation therapy, or both, is associated with a favorable
clinical outcome for a selected subgroup of patients with
ILNR of OC [3,6-9]. In the present case, the patient
underwent surgical resection of ILNR and adjuvant
chemotherapy and was free of disease at a follow-up
consultation 29 months after the first notice of relapse.Conclusions
Peripheral ILNR, including RSCLN, could occur without
a macroscopic abdominal lesion. Clinicians should care-
fully examine peripheral lymph nodes for recurrence.
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